Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 12/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20116162 | 0.87 | TBK1 (0.37) | MAPTSMN1; SMN2S1PR1LMNAMAPK1 | |
| SCHEMBL20116074 | 0.86 | PIK3CA (0.37) | MAPTHTTS1PR1LMNA | |
| SCHEMBL22358046 | 0.85 | HDAC1 (0.38) | MAPTSMN1; SMN2HTTS1PR1LMNA | |
| SCHEMBL20117088 | 0.84 | TBK1 (0.35) | MAPTSMN1; SMN2S1PR1LMNAMAPK1 | |
| SCHEMBL20116161 | 0.84 | TBK1 (0.39) | MAPTSMN1; SMN2HTTS1PR1LMNA | |
| SCHEMBL20116169 | 0.83 | S1PR1 (0.35) | S1PR1 | |
| SCHEMBL20116144 | 0.83 | PIK3CA (0.36) | MAPTHTTS1PR1LMNA | |
| SCHEMBL20116183 | 0.82 | S1PR1 (0.43) | MAPTS1PR1LMNAMAPK1TSHR | |
| SCHEMBL20116391 | 0.82 | FASN (0.35) | MAPTHTTS1PR1LMNA | |
| SCHEMBL22358310 | 0.81 | S1PR1 (0.35) | S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| US-20200262828-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873298-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | MAPT 22/4885SMN1; SMN2 13/4885HTT 6/4885 |
| US-20200262828-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | MAPT 22/4885SMN1; SMN2 13/4885HTT 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.